Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1096-1099

  Saito, Tomoaki ^a,b   Kimura, Soichiro ^a   Tateda, Kazuhiro ^a   Mori, Nobuaki ^a   Hosono, Natsue ^a   Hayakawa, Kayoko ^a   Akasaka, Yoshikiyo ^a   Ishii, Toshiharu ^a   Sumiyama, Yoshinobu ^b   Kusachi, Shinya ^b   Nagao, Jiro ^b   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Apoptosis; FasL; Toxin A

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; FAS LIGAND; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL DAMAGE; CELL VIABILITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; FEMALE; HEP 2 CELL; IN VITRO STUDY; LETHALITY; MOUSE; NONHUMAN; SURVIVAL RATE; TREATMENT RESPONSE;

ANIMALS; ANTITOXINS; CELL LINE; CELL SURVIVAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; HEPATOCYTES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; L-LACTATE DEHYDROGENASE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79954582154     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr027     Document Type: Article

References (10)

1. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359: 1932-40.
2. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
3. Genth H, Dreger SC, Huelsenbeck J et al. Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 2008; 40: 592-7.
4. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247-63.
5. McPherson S, Rees CJ, Ellis R et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640-5.
6. Ueda C, Tateda K, Horikawa M et al. Anti-Clostridium difficile potential of tetramic acid derivatives from Pseudomonas aeruginosa quorumsensing autoinducers. Antimicrob Agents Chemother 2010; 54: 683-8.
7. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
8. Babcock GJ, Broering TJ, Hernandez HJ et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006; 74: 6339-47.
9. Corthier G, Muller MC, Wilkins TD et al. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991; 59: 1192-5.
10. Kim H, Rhee SH, Pothoulakis C et al. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007; 133: 875-86.